BiOptix Diagnostics, Inc.: Series A $3M

Posted in I - Series A, Q - 1Q09, R - ROCKY MOUNTAIN, X - Device (Diagnostic), XX - CO

BiOptix (Boulder, CO) a commercial focused developer of an array-based biomolecule detection system that addresses many markets that currently cannot obtain the needed sensitivity and throughput in a single solution, closed a $3M Series A finacing. Participants include Boulder Ventures.

OPX Biotechnologies, Inc.: Series B $12.1M

Posted in I - Series C, Q - 1Q09, R - ROCKY MOUNTAIN, X - Bioagriculture, X - Biofuel, XX - CO

OPX Biotechnologies (Boulder, CO) a research-stage biofuels company using synthetic biology to engineer the microbes as a renewable fuel source closed a $12.1M Series B financing. Participants include Braemar Energy Ventures, Mohr Davidow Ventures and X/Seed Capital.

MD-IT, Inc.: Series B $11M

Posted in I - Series B, Q - 1Q09, R - ROCKY MOUNTAIN, X - TeleMedicine, XX - CO

MD-IT (Boulder, CO) pprovider of medical documentation services and software for physician offices and ambulatory clinics, closed a $11M Series B financing. Participants include J. Burke Capital Partners.

Accera, Inc.: Series C $35M

Posted in I - Series C, Q - 4Q08, R - ROCKY MOUNTAIN, X - Alzheimer's, X - Medical Food

Accera (Broomfield, CO) a biotechnology company developing therapies that address metabolic deficiencies and provide an alternative energy source for brain cells, closed a $35M Series C financing. Participants include Inventages Venture Capital, POSCO BioVentures and Bloodstone Ventures.

Prolexys Pharmaceuticals, Inc.: Series A $20M

Posted in I - Series A, Q - 4Q08, R - ROCKY MOUNTAIN, X - Cardiology, X - Oncology

Prolexys Pharmaceuticals (Salt Lake City, UT) early-stage developer of cancer and cardiovascular small molecule drugs, closed a $20M Series A financing. Participants include Friedli Corporate Finance.

MicroPhage, Inc.: Series A $11M

Posted in I - Series A, Q - 4Q08, R - ROCKY MOUNTAIN, X - Bacteriophage, X - Device (Diagnostic)

MicroPhage (Longmont, CO) early-stage developer of bacteriophage-based bacterial identification and antibiotic susceptibility and resistance testing, closed $11M Series A financing.
Participants include ?

AlloCure, Inc.: Series A $14.5M

Posted in I - Series A, Q - 3Q08, R - ROCKY MOUNTAIN, X - Renal

AlloCure (Germany, UT) a cell therapy company focused on acute kidney injury closed a $14.5M Series A financing. Participants include SV Life Sciences and Novo AS.

Sierra Neuropharmaceuticals: Series A $21.5M

Posted in I - Series A, Q - 3Q08, R - ROCKY MOUNTAIN, X - Epilepsy, X - Neurology, X - Schizophrenia

Sierra Neuropharmaceuticals (Aurora, CO) development-stage biopharmaceutical company specializing treating neurological disorders, closed a $21.5M Series A financing. Participants include HealthCare Ventures, Morgenthaler Ventures, Sequel Ventures and High Country Venture.

Miragen, Inc.: Series A $8M

Posted in I - Series A, Q - 2Q08, R - ROCKY MOUNTAIN, X - Cardiology, X - RNAi, X - miRNA

Miragen (Boulder, CO) development-stage company focused on the treatment of cardiovascular and muscle disease based on microRNA biology, closed a $8M Series A financing. Participants include Atlas Venture and Boulder Ventures.

SomaLogic, Inc: Series D $35M

Posted in I - Series D, Q - 2Q08, R - ROCKY MOUNTAIN, X - Device (Diagnostic), X - Proteomics

SomaLogic (Boulder, CO) early-stage company focused on proteomics systems for medical diagnostics, closed a $35M Series D financing. Participants include Otsuka Pharmaceutical, Stronghold Capital, ProQuest Investments, Profundix and Quest Diagnostics.

« Previous Entries Next Entries »

to top of page...